| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| 2500% | ₹764.2 0% | 2,600 | ₹0.5 0% | 2500% |
| 5000% | ₹587 0% | 2,800 | ₹3.15 0% | 4,0000% |
| - | - | 2,900 | ₹3.3 -9.58% | 14,500-9.37% |
| 5000% | ₹425.95 0% | 2,950 | ₹4.3 2.38% | 7,2507.40% |
| 7500% | ₹252.85 0% | 3,000 | ₹5.9 -8.52% | 56,000-0.44% |
| 5000% | ₹366.8 0% | 3,050 | ₹7.7 -15.84% | 14,7507.27% |
| 1,5000% | ₹326.7 1.66% | 3,100 | ₹11.5 -12.21% | 54,50011.22% |
| 1,25066.66% | ₹280.7 0.6% | 3,150 | ₹16.7 -13.24% | 9,0002.85% |
| 20,00015.94% | ₹250 0.54% | 3,200 | ₹23.7 -11.06% | 44,000-12% |
| 18,5004.22% | ₹208 -0.76% | 3,250 | ₹32.75 -11.84% | 33,50067.5% |
| 48,250-10.64% | ₹175 1.09% | 3,300 | ₹45.05 -10.96% | 58,0007.40% |
| 51,2504.06% | ₹142.1 0.63% | 3,350 | ₹61.65 -8.93% | 35,500-18.39% |
| 1,38,250-4.65% | ₹113.6 1.02% | 3,400 | ₹83.25 -5.77% | 95,25012.05% |
| 79,00028.97% | ₹88.95 -0.05% | 3,450 | ₹106.05 -5.77% | 11,75023.68% |
| 1,28,7501.77% | ₹67.35 -2.39% | 3,500 | ₹136.1 -5.48% | 7,750-13.88% |
| 49,50022.22% | ₹50.85 -2.86% | 3,550 | ₹170.15 -5.94% | 1,250-28.57% |
| 2,14,000-2.94% | ₹37.35 -3.98% | 3,600 | ₹215 -16.68% | 1,500200% |
| 36,50028.07% | ₹27.85 -6.85% | 3,650 | - | - |
| 91,250-3.69% | ₹20.75 -8.99% | 3,700 | ₹361.85 0% | 5000% |
| 2,5000% | ₹15.3 0% | 3,750 | - | - |
| 85,000-2.29% | ₹11.4 -15.24% | 3,800 | - | - |
| 17,5000% | ₹7.1 0% | 3,900 | - | - |
The acquisition values JB Chemicals at ₹25,689 crore on a fully diluted basis, according to the company’s official announcement.
On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.
Here are some of the stocks that may see significant price movement today: JK Cement, KEC International, Macrotech Developers, etc.
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
The company announced that its India business grew by 10% year on year in the June quarter, with sales rising to ₹1,635 Crore from ₹1,426 Crore in Q1 FY24.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
